Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most popular fund investment industries, there are Health Care, Biotechnology. Among the most popular portfolio startups of the fund, we may highlight Neuraly.
The typical case for the fund is to invest in rounds with 7 participants. The meaningful sponsors for the fund in investment in the same round are Smilegate Investment, Magna Investment, LB Investment.
The high activity for fund was in 2018. The usual things for fund are deals in the range of 50 - 100 millions dollars. The fund is constantly included in less than 2 deals per year.
Related Funds
| Fund Name | Location |
| Apple Tree Partners | New York, New York, United States |
| Brain Power | China, Guangdong, Shenzhen |
| Broadband Venture Partners | Dallas, Texas, United States |
| Cadence Bancorp | Houston, Texas, United States |
| CHANEL | France, Ile-de-France, Neuilly-sur-seine |
| Changying Technology | China, Guangdong Province, Maoming City |
| City National Bank | California, Los Angeles, United States |
| CorLyst, LLC | Ellicott City, Maryland, United States |
| CRYSTAL VENTURES | - |
| IDFC Mutual Fund | India, Maharashtra, Mumbai |
| Kaplan | Florida, Fort Lauderdale, United States |
| Logitech Investments | - |
| MCB Salt | - |
| Mendes | - |
| Ministry of Business, Innovation and Employment | New Zealand, Wellington, Wellington |
| Miteno | Beijing, Beijing, China |
| Naos | - |
| WERU Investment | Chiyoda, Japan |
| Youguang Network | China, Shanghai, Xuhui |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
D&D Pharmatech | $137M | 14 Aug 2019 | Seongnam-si, Gyeonggi-do, South Korea | ||
Neuraly | $36M | 18 Jul 2018 | Maryland, United States | ||
D&D Pharmatech | $36M | 01 Jan 2018 | Seongnam-si |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
D&D Pharmatech | $137M | 14 Aug 2019 | Seongnam-si, Gyeonggi-do, South Korea | ||
Neuraly | $36M | 18 Jul 2018 | Maryland, United States | ||
D&D Pharmatech | $36M | 01 Jan 2018 | Seongnam-si |
